Results 11 to 20 of about 67,063 (322)
Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies [PDF]
BMC Musculoskeletal Disorders, 2009 Background Occurrence of atrial fibrillation (AF) amongst bisphosphonate users has been increasingly reported but results are conflicting. We performed a Bayesian meta-analysis to address the possible association between the occurrence of AF and ...
Cheak Alicia +4 more
doaj +3 more sources
Endocrinology and Metabolism Clinics of North America, 2003 Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve
Julie T, Lin, Joseph M, Lane
openaire +7 more sources
Frontiers in Medicine, 2021 Bisphosphonate has great potential in KOA therapy, but whether the anti-resorption mechanism of bisphosphonate aggravates sclerosis of subchondral bone remains unclear.
Mingyang Li +7 more
doaj +1 more source
Annals of the New York Academy of Sciences, 2006 Abstract: Bisphosphonates belong to a class of compounds similar to pyrophosphate. In these compounds the oxygen atom of the pyrophosphate is replaced by a carbon atom resulting in a P‐C‐P bond. They exert a potent inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. They reduce bone turnover, increase bone mineral density,
Lambrinoudaki, I. +2 more
+7 more sources
How much we know about bisphosphonate lesions [PDF]
Acta Stomatologica Naissi, 2016 Introduction: Bisphosphonate drugs are used in the treatment of the osteoporosis and malignant processes in the bone tissue. As a result of this use bisphosphonate lesions are formed in bone tissue and oral mucosis, which representing a remarkable ...
Pešić Zoran +2 more
doaj +1 more source
Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients
Brazilian Journal of Otorhinolaryngology, 2022 Introduction: Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient’s quality pf life.
Aristilia Pricila Tahara Kemp +7 more
doaj +1 more source
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. [PDF]
, 2013 Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint ...
AD Beswick +37 more
core +5 more sources
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]
, 2011 The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong +7 more
core +4 more sources
Bisphosphonate nephrotoxicity [PDF]
Kidney International, 2008 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Perazella, Mark A., Markowitz, Glen S.
openaire +2 more sources
Medical and Health Science Journal, 2020 INTRODUCTION Osteogenesis imperfecta (OI) or brittle bone disease is a connective tissue formation disorder that is generally characterized by bone fragility, osteopenia, blue sclera, dentinogenesis imperfecta (DI), and hearing loss.
Baskoro Kusumo Riswanto +1 more
doaj +1 more source